ATE169058T1 - Gegen cd3 gerichtete antikörper - Google Patents

Gegen cd3 gerichtete antikörper

Info

Publication number
ATE169058T1
ATE169058T1 AT91917169T AT91917169T ATE169058T1 AT E169058 T1 ATE169058 T1 AT E169058T1 AT 91917169 T AT91917169 T AT 91917169T AT 91917169 T AT91917169 T AT 91917169T AT E169058 T1 ATE169058 T1 AT E169058T1
Authority
AT
Austria
Prior art keywords
ser
tyr
gly
asp
asn
Prior art date
Application number
AT91917169T
Other languages
English (en)
Inventor
Scott David Gorman
Edward Graham Routledge
Herman Waldmann
Original Assignee
British Tech Group
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by British Tech Group filed Critical British Tech Group
Application granted granted Critical
Publication of ATE169058T1 publication Critical patent/ATE169058T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/464—Igs containing CDR-residues from one specie grafted between FR-residues from another
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT91917169T 1990-10-05 1991-10-04 Gegen cd3 gerichtete antikörper ATE169058T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB909021679A GB9021679D0 (en) 1990-10-05 1990-10-05 Antibody preparation

Publications (1)

Publication Number Publication Date
ATE169058T1 true ATE169058T1 (de) 1998-08-15

Family

ID=10683287

Family Applications (1)

Application Number Title Priority Date Filing Date
AT91917169T ATE169058T1 (de) 1990-10-05 1991-10-04 Gegen cd3 gerichtete antikörper

Country Status (12)

Country Link
EP (1) EP0504350B1 (de)
JP (1) JP3081641B2 (de)
KR (1) KR100245564B1 (de)
AT (1) ATE169058T1 (de)
AU (1) AU651623B2 (de)
CA (1) CA2070659C (de)
DE (1) DE69129896T2 (de)
ES (1) ES2121788T3 (de)
GB (2) GB9021679D0 (de)
NZ (1) NZ240080A (de)
WO (1) WO1992006193A1 (de)
ZA (1) ZA917960B (de)

Families Citing this family (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8928874D0 (en) * 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
GB9021679D0 (en) * 1990-10-05 1990-11-21 Gorman Scott David Antibody preparation
CA2065658A1 (en) * 1991-04-19 1992-10-20 Tse-Wen Chang Conjugates of liposomes or microbeads and antibodies specific for t lymphocytes and their use in vivo immune modulators
US6129916A (en) * 1991-04-19 2000-10-10 Tanox, Inc. Method of Increasing activation on proliferation of T cells using antibody-microbead conjugates
US5872222A (en) * 1991-04-19 1999-02-16 Tanox Biosystems, Inc. Conjugates of polymers and antibodies specific for T lymphocytes, and their use as adjuvants
US6106835A (en) * 1991-04-19 2000-08-22 Tanox, Inc. Modified binding molecules specific for T or B lymphocytes and their use as in vivo immune modulators
US6197298B1 (en) 1991-04-19 2001-03-06 Tanox, Inc. Modified binding molecules specific for T lymphocytes and their use as in vivo immune modulators in animals
US5817308A (en) 1994-02-14 1998-10-06 University Of Rochester Tolerogenic fusion proteins of immunoglobulins and methods for inducing and maintaining tolerance
US7153508B2 (en) 1995-06-07 2006-12-26 Biogen Idec Inc. Treatment of B cell lymphoma using anti-CD80 antibodies that do not inhibit the binding of CD80 to CTLA-4
US7175847B1 (en) 1995-06-07 2007-02-13 Biogen Idec Inc. Treating intestinal inflammation with anti-CD80 antibodies that do not inhibit CD80 binding to CTLA-4
US6113898A (en) 1995-06-07 2000-09-05 Idec Pharmaceuticals Corporation Human B7.1-specific primatized antibodies and transfectomas expressing said antibodies
EP0977862B8 (de) 1997-04-30 2009-09-16 Twinstrand Therapeutics Inc. Ricin-ähnliche toxine zur therapie von kreb, viraler oder parasitärer infektionen
PT2045322E (pt) 1997-07-14 2015-10-16 Université de Liège Musculatura dupla em mamíferos
US6103466A (en) * 1997-07-14 2000-08-15 University Of Liege Double-muscling in mammals
GB9815909D0 (en) 1998-07-21 1998-09-16 Btg Int Ltd Antibody preparation
US6531125B1 (en) 1999-03-02 2003-03-11 Twinstrand Therapeutics Inc. Antiviral ricin-like proteins
CA2305716A1 (en) 1999-05-28 2000-11-28 University Of Guelph Method for assay of wbpm
US20030031675A1 (en) 2000-06-06 2003-02-13 Mikesell Glen E. B7-related nucleic acids and polypeptides useful for immunomodulation
EP1499635B8 (de) 2002-05-02 2014-04-16 David Lovejoy Teneurin c-terminal assoziierte peptide und deren verwendungen
JP5576010B2 (ja) 2003-08-04 2014-08-20 ザ・ホスピタル・フォー・シック・チルドレン ラフォラ病遺伝子
US7427670B2 (en) 2003-12-19 2008-09-23 Cytochroma Inc. Cytochrome P450 24 (CYP24) monoclonal antibody and methods and uses thereof
TWI384069B (zh) 2004-08-27 2013-02-01 Pfizer Ireland Pharmaceuticals 多胜肽之製法
US7300773B2 (en) 2004-08-27 2007-11-27 Wyeth Research Ireland Limited Production of TNFR-Ig
TWI374935B (en) 2004-08-27 2012-10-21 Pfizer Ireland Pharmaceuticals Production of α-abeta
JP5014157B2 (ja) 2005-02-16 2012-08-29 ユニバーシティー オブ チューリッヒ 改良免疫毒素を用いた癌治療法
TWI417301B (zh) 2006-02-21 2013-12-01 Wyeth Corp 對抗人類介白素-２２（ｉｌ-２２）之抗體及其用途
TW200744634A (en) 2006-02-21 2007-12-16 Wyeth Corp Methods of using antibodies against human IL-22
KR101495549B1 (ko) 2006-07-13 2015-02-25 와이어쓰 엘엘씨 당단백질의 생산
ES2625798T3 (es) * 2006-10-02 2017-07-20 E. R. Squibb & Sons, L.L.C. Anticuerpos humanos que se unen a CXCR4 y usos de los mismos
MX2009003542A (es) 2006-10-12 2009-04-15 Wyeth Corp Metodos y composiciones con opalescencia reducida.
US8192951B2 (en) 2006-11-03 2012-06-05 Wyeth Llc Glycolysis-inhibiting substances in cell culture
US20110294782A1 (en) 2006-11-10 2011-12-01 Massachusetts Institute Of Technology Small molecule pak inhibitors
DE102006062398A1 (de) 2006-12-20 2008-06-26 Edi (Experimentelle & Diagnostische Immunologie) Gmbh Verfahren zur Erkennung und/oder Charakterisierung zellulärer Aktivitätsmuster, Verwendung von Toll-like-Rezeptor-Liganden (TLR-Liganden) und ein Kit
RU2009132986A (ru) 2007-03-02 2011-04-10 Уайт (Us) Применение меди и глутамата в культуре клеток для производства полипептидов
TW200902708A (en) 2007-04-23 2009-01-16 Wyeth Corp Methods of protein production using anti-senescence compounds
US20100075329A1 (en) 2008-09-23 2010-03-25 O'toole Margot Methods for predicting production of activating signals by cross-linked binding proteins
KR101593285B1 (ko) 2008-10-29 2016-02-11 아블린쓰 엔.브이. 단일 도메인 항원 결합 분자의 제형
CA2739352C (en) 2008-10-29 2021-07-13 Wyeth Llc Methods for purification of single domain antigen binding molecules
US9085795B2 (en) 2009-02-04 2015-07-21 Molecular Innovations, Inc. Methods for screening candidate agents for modulating prorenin and renin, assays for detecting prorenin and antibodies
JP5925116B2 (ja) 2009-04-29 2016-05-25 ザ・ヘンリー・エム・ジャクソン・ファンデイション・フォー・ジ・アドヴァンスメント・オヴ・ミリタリー・メディシン、インコーポレイテッド Ｅｒｇモノクローナル抗体
CN102481380A (zh) 2009-07-09 2012-05-30 霍夫曼-拉罗奇有限公司 体内肿瘤血管系统成像
SG183854A1 (en) 2010-03-03 2012-10-30 Univ British Columbia Oligomer-specific amyloid beta epitope and antibodies
WO2012007880A2 (en) 2010-07-16 2012-01-19 Ablynx Nv Modified single domain antigen binding molecules and uses thereof
EP2420250A1 (de) 2010-08-13 2012-02-22 Universitätsklinikum Münster Anti-Syndecan-4-Antikörper
WO2012023085A1 (en) 2010-08-20 2012-02-23 Wyeth Llc Cell culture of growth factor-free adapted cells
US20130273055A1 (en) 2010-11-16 2013-10-17 Eric Borges Agents and methods for treating diseases that correlate with bcma expression
CN106039306A (zh) 2011-03-30 2016-10-26 埃博灵克斯股份有限公司 使用针对TNFα的单结构域抗体治疗免疫病症的方法
CA2852021C (en) 2011-10-21 2018-08-28 Pfizer Inc. Addition of iron to improve cell culture
HK1212237A1 (en) 2012-08-31 2016-06-10 University Of Virginia Patent Foundation Target peptides for immunotherapy and diagnostics
EP4088737A3 (de) 2012-09-05 2023-02-08 University Of Virginia Patent Foundation Target-peptide für therapie und diagnostik von kolorektalkarzinomen
EP2903692B1 (de) 2012-10-08 2019-12-25 St. Jude Children's Research Hospital Therapien auf der basis der steuerung der stabilität und funktion regulatorischer t-zellen über eine neuropilin-1:semaphorin-achse
US20160000893A1 (en) 2012-12-13 2016-01-07 University Of Virginia Patent Foundation Target peptides for ovarian cancer therapy and diagnostics
JP6693872B2 (ja) 2013-07-25 2020-05-13 シトムクス セラピューティクス，インコーポレイティド 多重特異性抗体、多重特異性活性化可能抗体、及びそれらの使用方法
EP4512889A3 (de) 2014-03-19 2025-05-07 Pfizer Inc. Zellkultur-verfahren
EP3137100B1 (de) 2014-04-15 2023-12-20 University Of Virginia Patent Foundation Isolierte t-zellenrezeptoren und verfahren zur verwendung davon
WO2016014974A2 (en) 2014-07-25 2016-01-28 Cytomx Therapeutics, Inc. Anti-cd3 antibodies, activatable anti-cd3 antibodies, multispecific anti-cd3 antibodies, multispecific activatable anti-cd3 antibodies, and methods of using the same
AU2016306304A1 (en) 2015-08-07 2018-03-22 The University Of Birmingham Identification of class I MHC associated glycopertides as targets for cancer immunotherapy
CA3214798A1 (en) 2015-09-23 2017-03-30 Pfizer Inc. Cells and method of cell culture
GB201520191D0 (en) 2015-11-16 2015-12-30 Cancer Rec Tech Ltd T-cell receptor and uses thereof
CA3019753C (en) 2016-04-05 2021-10-26 Pfizer Inc. Cell culture process
JP7461741B2 (ja) 2016-06-20 2024-04-04 カイマブ・リミテッド 抗ｐｄ－ｌ１およびｉｌ－２サイトカイン
US20200056190A1 (en) 2017-03-16 2020-02-20 Pfizer Inc. Tyrosine prototrophy
EP3630830A1 (de) 2017-05-23 2020-04-08 Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Neuer cd73-antikörper, herstellung und verwendungen davon
JP2020533983A (ja) 2017-09-15 2020-11-26 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 目的のポリペプチドのラージスケールの製造間のオンラインバイオマス静電容量モニタリング
EP3743101A2 (de) 2018-01-25 2020-12-02 ACM Biolabs Pte Ltd Ein lösliches verkapseltes antigen enthaltende polymersome sowie verfahren zu deren herstellung und verwendung
CN111902160B (zh) 2018-03-16 2025-05-09 百时美施贵宝公司 蛋白质生产期间的代谢酶活性和二硫键还原
EP4253958A3 (de) 2018-03-26 2023-12-06 Glycanostics s.r.o. Mittel und verfahren zur glykoprofilierung eines proteins
CN112996539A (zh) 2018-09-12 2021-06-18 Acm生物实验室私人有限公司 包含共价结合的抗原的聚合物囊泡以及其制备方法和用途
JP2022513702A (ja) 2018-12-06 2022-02-09 ファイザー・インク 阻害剤産生が低下した細胞およびその使用方法
EP4025303A1 (de) 2019-09-04 2022-07-13 Deutsches Zentrum für Neurodegenerative Erkrankungen e.V. (DZNE) Herv-inhibitoren zur verwendung bei der behandlung von tauopathien
WO2022218957A1 (en) 2021-04-12 2022-10-20 Acm Biolabs Pte Ltd Polymersomes comprising a soluble encapsulated polynucleotide and an ionizable lipid as well as methods of making and uses thereof
CA3228822A1 (en) 2021-08-26 2023-03-02 Jan Tkac Glycoprotein biomarkers for diagnosing cancer
US20240385193A1 (en) 2021-09-14 2024-11-21 Glycanostics S.R.O. Use of lectins to determine mammaglobin-a glycoforms in breast cancer
WO2023079058A1 (en) 2021-11-05 2023-05-11 Yokogawa Insilico Biotechnology Gmbh Cell culture with reduced production of lactate
KR20240139082A (ko) 2022-02-02 2024-09-20 화이자 인코포레이티드 시스테인 프로토트로피
CN115073602B (zh) * 2022-05-30 2023-10-03 苏州百道医疗科技有限公司 一种抗cd3重组兔单克隆抗体及其应用
EP4698631A1 (de) 2023-04-21 2026-02-25 Pfizer Inc. Verbesserte zellen und zellkulturen

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI105320B (fi) * 1988-04-04 2000-07-31 Oncogen Menetelmä vasta-aineheterokonjugaattien valmistamiseksi, joita käytetään imusoluaktiivisuuden säätelyssä ja diagnoosissa
GB8928874D0 (en) * 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
GB9021679D0 (en) * 1990-10-05 1990-11-21 Gorman Scott David Antibody preparation

Also Published As

Publication number Publication date
GB9121126D0 (en) 1991-11-13
EP0504350B1 (de) 1998-07-29
DE69129896T2 (de) 1998-12-10
KR927003816A (ko) 1992-12-18
GB2249310A (en) 1992-05-06
GB2249310B (en) 1994-08-03
ZA917960B (en) 1993-04-05
WO1992006193A1 (en) 1992-04-16
JP3081641B2 (ja) 2000-08-28
NZ240080A (en) 1995-05-26
EP0504350A1 (de) 1992-09-23
KR100245564B1 (ko) 2000-02-15
JPH05502384A (ja) 1993-04-28
GB9021679D0 (en) 1990-11-21
ES2121788T3 (es) 1998-12-16
AU651623B2 (en) 1994-07-28
CA2070659C (en) 2001-04-24
CA2070659A1 (en) 1992-04-06
DE69129896D1 (de) 1998-09-03
AU8546891A (en) 1992-04-28

Similar Documents

Publication Publication Date Title
DE69129896D1 (de) Gegen cd3 gerichtete antikörper
ATE384792T1 (de) Antikörpervarianten mit höheren bindungsaffinitäten im vergleich zu parentalen antikörpern
DE69433406D1 (de) Antikörper gegen cd40
ATE155818T1 (de) Nicht glycosylierter anti-cd3-igg-antikörper
SE9304060D0 (sv) Sätt att selektera specifika bakteriofager
ATE301471T1 (de) Verwendung von antikörpen gegen cd45ro leukozytenantigen zur immunmodulation
ATE123780T1 (de) Verfahren zur verwendung und herstellung von peptiden.
CA2212750A1 (en) Humanized antibodies against cd3
MX9603080A (es) Anticuerpos monoclonales inmuno-estimulantes.
EP0728215A4 (de) METHODE ZUR BINDUNG VON MATERIAL AN DAS -g(b)-AMYLOID-PEPTID
DE69535133D1 (de) Humanisierte antikörper gegen das leukozytenadhäsionsmolekül vla-4
GR1002306B (el) Αναλυση και διαταξη συγκολλησεως στηλης.
FI891528A0 (fi) Antikroppheterokonjugat foer anvaendning vid reglering av lymfocytaktivitet.
NO973875D0 (no) Fremgangsmåte for simulering av en immunrespons
ES2079621T3 (es) Procedimiento de identificacion o de titulacion de proteinas y aplicaciones.
HU9602570D0 (en) Process for producing immunoglobulines from fractions produced with fractioning human blood-plasma
DE69615843D1 (de) Il-8 antagonisten zur behandlung von asthma
DE3485712D1 (de) Monoklonale antikoerper gegen menschliche nierenkrebsantigene und verfahren.
DE3888604D1 (de) Monoklonale Antikörper gegen Antithrombinbindende Substanz und seine Verwendungen.
NO953749L (no) Hepatitt B-escapemutantspesifikke bindingsmolekyler
DE3570677D1 (en) Acino-foetal differentiation proteins associated with cancer of the pancreas, antiserum and monoclonal antibodies against these proteins and processes for their preparation
DE59207362D1 (de) Monoklonale Antikörper gegen den Plasmin-Antiplasmin Komplex, Verfahren zu ihrer Herstellung sowie ihre Verwendung
DE68912165D1 (de) Monoklonaler Antikörper, der fähig ist, ein mit humaner Arteriosklerose assoziiertes Antigen zu erkennen und Verfahren zu seiner Herstellung.
DK494084A (da) Hybridoma, monokloniske antistoffer frembragt hermed og diagnosemetode under anvendelse af disse
HUP0003029A2 (hu) Ankrod specifikus monoklonális antitestek, antitestfragmentumok, keverékeik és alkalmazásuk

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
EELA Cancelled due to lapse of time